Literature DB >> 29371747

A convergent, scalable and stereoselective synthesis of azole CYP51 inhibitors.

Galina Lepesheva1, Plamen Christov1, Gary A Sulikowski1, Kwangho Kim1.   

Abstract

The study and development of azole-based CYP51 inhibitors is an active area of research across disciplines of biochemistry, pharmacology and infectious disease. Support of in vitro and in vivo studies require the development of robust asymmetric routes to single enantiomer products of this class of compounds. Herein, we describe a scalable and enantioselective synthesis to VNI and VFV, the two potent inhibitors of protozoan sterol 14α-demethylase (CYP51) that are currently under consideration for clinical trials for Chagas disease. A key transformation is the Jacobsen Hydrolytic Kinetic Resolution (HKR) reaction. The utility of the synthetic route is illustrated by the preparation of >25 g quantities of single enantiomers of VNI and VFV.

Entities:  

Keywords:  Azole; Enzyme inhibitor; Kinetic resolution; Stereospecific

Year:  2017        PMID: 29371747      PMCID: PMC5777588          DOI: 10.1016/j.tetlet.2017.09.070

Source DB:  PubMed          Journal:  Tetrahedron Lett        ISSN: 0040-4039            Impact factor:   2.415


  20 in total

1.  Asymmetric catalysis with water: efficient kinetic resolution of terminal epoxides by means of catalytic hydrolysis.

Authors:  M Tokunaga; J F Larrow; F Kakiuchi; E N Jacobsen
Journal:  Science       Date:  1997-08-15       Impact factor: 47.728

2.  A switch in enantiomer preference between mitochondrial F1F0-ATPase chemotypes.

Authors:  Sharon N Bisaha; Mary F Malley; Andrew Pudzianowski; Hossain Monshizadegan; Paulina Wang; Cort S Madsen; Jack Z Gougoutas; Philip D Stein
Journal:  Bioorg Med Chem Lett       Date:  2005-06-02       Impact factor: 2.823

3.  The role of fluorine substitution in biphenyl methylene imidazole-type CYP17 inhibitors for the treatment of prostate carcinoma.

Authors:  Qingzhong Hu; Matthias Negri; Sureyya Olgen; Rolf W Hartmann
Journal:  ChemMedChem       Date:  2010-06-07       Impact factor: 3.466

Review 4.  Sterol 14alpha-demethylase (CYP51) as a therapeutic target for human trypanosomiasis and leishmaniasis.

Authors:  Galina I Lepesheva; Michael R Waterman
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

5.  Antitrypanosomal Activity of Sterol 14α-Demethylase (CYP51) Inhibitors VNI and VFV in the Swiss Mouse Models of Chagas Disease Induced by the Trypanosoma cruzi Y Strain.

Authors:  F H Guedes-da-Silva; D G J Batista; C F Da Silva; J S De Araújo; B P Pavão; M R Simões-Silva; M M Batista; K C Demarque; O C Moreira; C Britto; G I Lepesheva; M N C Soeiro
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

6.  VFV as a New Effective CYP51 Structure-Derived Drug Candidate for Chagas Disease and Visceral Leishmaniasis.

Authors:  Galina I Lepesheva; Tatiana Y Hargrove; Girish Rachakonda; Zdzislaw Wawrzak; Sébastien Pomel; Sandrine Cojean; Pius N Nde; W David Nes; Charles W Locuson; M Wade Calcutt; Michael R Waterman; J Scott Daniels; Philippe M Loiseau; Fernando Villalta
Journal:  J Infect Dis       Date:  2015-04-15       Impact factor: 5.226

7.  VNI cures acute and chronic experimental Chagas disease.

Authors:  Fernando Villalta; Mark C Dobish; Pius N Nde; Yulia Y Kleshchenko; Tatiana Y Hargrove; Candice A Johnson; Michael R Waterman; Jeffrey N Johnston; Galina I Lepesheva
Journal:  J Infect Dis       Date:  2013-01-31       Impact factor: 5.226

8.  In vitro and in vivo studies of the antiparasitic activity of sterol 14α-demethylase (CYP51) inhibitor VNI against drug-resistant strains of Trypanosoma cruzi.

Authors:  Maria de Nazaré Correia Soeiro; Elen Mello de Souza; Cristiane França da Silva; Denise da Gama Jaen Batista; Marcos Meuser Batista; Beatriz Philot Pavão; Julianna Siciliano Araújo; Claudia Alessandra Fortes Aiub; Patrícia Bernardino da Silva; Jessica Lionel; Constança Britto; Kwangho Kim; Gary Sulikowski; Tatiana Y Hargrove; Michael R Waterman; Galina I Lepesheva
Journal:  Antimicrob Agents Chemother       Date:  2013-06-17       Impact factor: 5.191

9.  Sterol 14alpha-demethylase as a potential target for antitrypanosomal therapy: enzyme inhibition and parasite cell growth.

Authors:  Galina I Lepesheva; Robert D Ott; Tatiana Y Hargrove; Yuliya Y Kleshchenko; Inge Schuster; W David Nes; George C Hill; Fernando Villalta; Michael R Waterman
Journal:  Chem Biol       Date:  2007-11

10.  CYP51 structures and structure-based development of novel, pathogen-specific inhibitory scaffolds.

Authors:  Tatiana Y Hargrove; Kwangho Kim; Maria de Nazaré Correia Soeiro; Cristiane França da Silva; Denise da Gama Jaen Batista; Marcos Meuser Batista; Eugenia M Yazlovitskaya; Michael R Waterman; Gary A Sulikowski; Galina I Lepesheva
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-06-30       Impact factor: 4.077

View more
  3 in total

1.  Relaxed Substrate Requirements of Sterol 14α-Demethylase from Naegleria fowleri Are Accompanied by Resistance to Inhibition.

Authors:  Tatiana Y Hargrove; Zdzislaw Wawrzak; Girish Rachakonda; W David Nes; Fernando Villalta; F Peter Guengerich; Galina I Lepesheva
Journal:  J Med Chem       Date:  2021-11-29       Impact factor: 7.446

2.  The Clinically Approved Antifungal Drug Posaconazole Inhibits Human Cytomegalovirus Replication.

Authors:  Beatrice Mercorelli; Anna Luganini; Marta Celegato; Giorgio Palù; Giorgio Gribaudo; Galina I Lepesheva; Arianna Loregian
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

Review 3.  Synthesis and Biological Activity of Sterol 14α-Demethylase and Sterol C24-Methyltransferase Inhibitors.

Authors:  David J Leaver
Journal:  Molecules       Date:  2018-07-17       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.